$110 Oil and a Blocked Strait: The Iran Shock Is Now Splitting Small-Cap Stocks in Two

The Iran war didn’t just push Brent crude past $100 a barrel — it drew a sharp line through the small-cap market, separating companies that are printing cash from those quietly bleeding out. One month in, that divide just got wider.

Brent crude surged 2.82% to $111.06 per barrel on Friday after two ultra-large container vessels owned by China Ocean Shipping Company — COSCO, the world’s fourth-largest shipping line by capacity — attempted to transit the Strait of Hormuz and were turned back. The incident carries significant weight: China is an ally of Iran, and Tehran had previously signaled that friendly nations’ ships could pass freely. The fact that even Chinese vessels are being blocked signals that Iran’s chokehold on the waterway remains firmly in place, despite diplomatic noise suggesting otherwise.

Iran controls access to a strait that handles roughly 20% of the world’s daily oil supply. Since the U.S.-Israeli strikes began on February 28, close to 500 million barrels of total liquids have been lost, with approximately 17.8 million barrels per day of oil and fuel flows disrupted, according to Rystad Energy. WTI, meanwhile, climbed to $97.01 on Friday — up from roughly $65 in February. The buffer that kept prices from going completely vertical is now gone. Rystad’s chief oil analyst described the global supply system as having shifted from “buffered to fragile,” with inventories drawn down to a point where there is little room left to absorb further shocks.

President Trump announced a 10-day pause on strikes targeting Iran’s energy infrastructure through April 6, and said talks were progressing — but markets barely reacted. The COSCO incident hit the same day, effectively negating any diplomatic optimism. Iran also reportedly allowed 10 oil tankers to pass through the strait this week as a goodwill gesture, but analysts were quick to caution that isolated shipments do not signal a reopening.

The Winners: Domestic Producers and LNG Players

The clearest beneficiaries are U.S.-based exploration and production companies with no Middle East operational exposure. They’re capturing elevated prices without the liability of stranded tankers, damaged facilities, or rerouting costs eating into the margins of globally integrated operators.

Small- and mid-cap names like Antero Resources (AR), Solaris Energy Infrastructure (SEI), and SM Energy (SM) have all been flagged by analysts as well-positioned to benefit from both higher prices and the scramble among European and Asian buyers to replace Persian Gulf supply. Antero in particular benefits from the LNG export surge — Asian LNG prices have skyrocketed more than 140% since the war began as Qatar halted exports, and U.S. natural gas producers with export exposure are capturing that spread directly. The SPDR S&P Oil & Gas Exploration & Production ETF (XOP) is up roughly 10% since the conflict started, significantly outpacing the broader market.

The Losers: Everyone Paying the Energy Tax

For small-cap companies outside the energy sector, $110 oil is a cost, not a catalyst. Airlines, regional manufacturers, consumer discretionary companies, and logistics-heavy businesses are absorbing higher input costs with limited pricing power and thin margins. Unlike large-caps with robust balance sheets, smaller companies can’t easily hedge energy exposure or wait out a prolonged commodity spike.

The macro backdrop makes it worse. The Russell 2000 entered correction territory this month and the timing is brutal. Approximately 32% of the debt held by Russell 2000 companies is floating-rate, meaning every basis point that rate-cut expectations get pushed back translates directly into higher interest expenses. With the Fed holding rates steady at its March 18 meeting and revising its inflation outlook higher, the one rate cut markets were pricing in for late 2026 is increasingly in doubt. Small-cap firms are facing approximately $368 billion in debt maturing in 2026 alone, much of it originally issued at near-zero rates — now needing to be refinanced at 6.5% to 8%.

Bank of America has noted that small caps with oil exposure but limited refinancing risk may be best positioned in the current environment. That framing is the right lens heading into Q1 earnings. The question isn’t whether oil stays at $110. It’s whether your small-cap holdings are collecting the windfall or paying the price for it — and with the Strait of Hormuz turning away even Chinese vessels, there’s no telling when this resolves.

SKYX Platforms (SKYX) – Tempered Near-Term Outlook, Long-Term Scaling Remains


Friday, March 27, 2026

Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q4 results. SKYX reported revenue of $24.9M versus our $26.5M estimate, reflecting a modest miss tied to the delayed rollout of the SKYFAN & Turbo Heater and disruption from its new AI-driven e-commerce platform. Adj. EBITDA loss of $2.7M was worse than our expectation of a loss of $0.4M.

Near-term catalysts. The SKYFAN & Turbo Heater has launched across major retailers, and we expect broader distribution and SKU expansion to support growth through 2026. The new AI-driven platform should improve conversion across the company’s owned websites following near-term disruption.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Newsmax (NMAX) – Among The Few Media Growth Companies


Friday, March 27, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Exceeds Q4 results. Newsmax delivered solid fourth quarter results with total revenue of $52.2 million, representing a 9.6% year-over-year increase, driven primarily by growth in broadcasting revenue, particularly affiliate fees and linear advertising demand. Importantly, profitability trends improved meaningfully, with adjusted EBITDA outperforming expectations, reflecting early signs of operating leverage despite continued investment in content and infrastructure.

Quarter Highlights: The quarter was characterized by strong execution across key operating metrics, including robust affiliate fee growth (+17.9%), continued resilience in advertising revenue, and significant audience expansion across both linear and streaming platforms. 


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Consumer Sentiment Just Hit a 3-Month Low

The American consumer is starting to crack, and the timing could not be worse for small-cap companies heading into earnings season.

The University of Michigan’s Index of Consumer Sentiment closed March at a final reading of 53.3 — below the 54 economists had forecast, down 5.8% from February, and the lowest reading since December. The drop was broad-based, cutting across all age groups and political affiliations, and it arrived just as small-cap stocks were already absorbing a brutal month of rising yields, a stalled rate-cut timeline, and a commodity shock with no clear end in sight.

The culprits are familiar by now: surging gas prices and stock market volatility tied directly to the Iran conflict. With the Strait of Hormuz still largely blocked and Brent crude trading above $110 per barrel, gas prices have risen more than $1 on average over the past month alone, according to AAA. That kind of increase hits consumers immediately and visibly — every fill-up is a reminder that something is wrong — and it has a well-documented drag on discretionary spending.

For small-cap companies, weakening consumer sentiment is not an abstract concern. These businesses — regional retailers, restaurant operators, consumer services companies, domestic manufacturers — are more directly exposed to shifts in consumer behavior than their large-cap counterparts, and they have fewer tools to manage the fallout. They can’t absorb margin compression as long, can’t hedge as efficiently, and don’t have the brand loyalty or pricing power that insulates household names from demand slowdowns.

The inflation expectations embedded in Friday’s data make the picture more complicated. Year-ahead inflation forecasts jumped to 3.8% from 3.4% in February — the largest single-month increase since April 2025, when sweeping global tariffs rattled markets. Long-term inflation expectations came in at 3.2%, still well above the pre-pandemic baseline. When consumers believe inflation is sticky, they pull back on big-ticket discretionary purchases and shift spending toward necessities. That behavioral shift flows directly into the revenue lines of the small-cap consumer sector.

There’s another dimension here that matters specifically to small-cap investors. Middle- and higher-income households reported some of the sharpest drops in sentiment this month, driven in part by stock market losses. With equity exposure now accounting for nearly 40% of household net worth — more than double its share during the oil shocks of the 1990s — market volatility has a faster and deeper psychological impact on consumer behavior than it did in previous energy crises. When portfolios fall, confidence follows, and discretionary spending follows confidence.

The S&P 500 is down 6.5% over the past month. The Dow is off 6.8%. The Russell 2000 has been even harder hit, entering correction territory earlier this month as the combination of higher-for-longer rates, a debt maturity wall, and energy-driven inflation converged at the worst possible time.

Consumer sentiment had been gradually recovering before March’s reversal, which means this isn’t a continuation of a trend — it’s a break in one. Whether it stabilizes or deteriorates further depends almost entirely on how long the Iran conflict persists and whether gas prices begin to pull back. Until there’s clarity on the Strait of Hormuz, small-cap consumer-facing companies should be approached with caution heading into Q1 earnings.

The data is speaking. The question is whether the market is listening.

Google’s Memory Efficiency Breakthrough Sends Chip Stocks Tumbling — But Is the Market Overreacting?

Memory chip stocks took a beating Thursday after Google went public with research on a new algorithm that could dramatically reduce the amount of memory needed to run large language models — rattling a sector that had been riding an AI-fueled supply crunch straight up.

Samsung Electronics and SK Hynix, the South Korean heavyweights that dominate the high-bandwidth memory market, both fell at least 6% in Seoul trading. In the U.S., Micron Technology (MU) slid more than 7%, while Western Digital and Sandisk each dropped at least 5%. Nvidia (NVDA) was not spared either, shedding nearly 4% as broader AI infrastructure sentiment soured.

What Google Actually Did

Google’s TurboQuant algorithm, which the company publicized on X this week — though the underlying research originally surfaced last year — claims to cut the memory required to run large language models by at least a factor of six. The efficiency gain targets what’s known as the key value cache, a critical bottleneck in AI inference, or the process of running AI models to generate outputs.

If widely adopted, TurboQuant could reduce the memory footprint of AI workloads significantly, theoretically easing the supply crunch that has sent chip prices and margins soaring across the sector.

The Bull Case Didn’t Disappear Overnight

Context matters here. Memory chip stocks had been on an extraordinary run. SK Hynix and Samsung shares had each surged more than 50% year-to-date through Wednesday, fueled by insatiable demand from hyperscalers building out AI infrastructure at historic scale. SK Group Chairman Chey Tae-won as recently as this week said the memory chip shortage would persist through 2030.

Morgan Stanley analyst Shawn Kim pushed back on the panic in a note, arguing the impact of Google’s research should ultimately be net positive for the industry. His logic: if AI models can run with materially lower memory requirements without sacrificing performance, the cost per query drops, making AI deployment more profitable and accelerating adoption — which in turn drives more demand for memory, not less.

Kim and analysts at JPMorgan and Citigroup all invoked the Jevons Paradox — a 19th century economic concept holding that greater efficiency in resource use tends to increase total consumption rather than reduce it. The same argument made the rounds when DeepSeek’s low-cost AI model rattled markets last year.

The Bigger Picture for Investors

The four largest hyperscalers — led by Amazon and Google — are collectively on track to spend roughly $650 billion this year on data center infrastructure. That spending appetite doesn’t evaporate because of one efficiency algorithm, and Ortus Advisors analyst Andrew Jackson noted the Google development may make little practical difference to near-term demand given how constrained supply remains.

For small and microcap investors with exposure to the memory supply chain — component manufacturers, equipment makers, or specialty materials companies — Thursday’s selloff may be more noise than signal. The structural demand drivers behind AI infrastructure spending remain firmly intact.

The more pressing question isn’t whether TurboQuant reduces memory demand. It’s whether the market had already priced in perfection for a sector where any efficiency headline is now treated as an existential threat.

Henkel Bets $1.4 Billion on Science-Backed Hair Care as OLAPLEX Era Ends on Nasdaq

German consumer goods giant Henkel AG is writing one of the largest checks in prestige hair care history, agreeing to acquire OLAPLEX Holdings (NASDAQ: OLPX) for approximately $1.4 billion in a cash deal that values shares at $2.06 apiece — a 55% premium over where the stock closed on March 25.

For small and microcap investors, this transaction is a textbook case study in what a strategic acquirer will pay for a brand with durable IP, a loyal professional channel, and a story of operational recovery.

From Lab Disruptor to Acquisition Target

OLAPLEX launched in 2014 with a singular innovation: Complete Bond Technology, a chemistry-driven approach to repairing hair bonds during and after chemical services. The product found its home in salons first, building a credibility-driven distribution model that competitors struggled to replicate.

Private equity firm Advent International backed the company and took it public, helping scale it from a single-product disruptor into a multi-SKU hair health platform. But OLAPLEX’s post-IPO journey has been rocky. The stock, which once traded well above $20, has languished amid slowing consumer demand, intense competition in the prestige hair segment, and a multi-year transformation program the company undertook to reset its cost structure, marketing engine, and go-to-market model.

That turnaround, while painful for shareholders who held on too long, appears to have made the company an attractive acquisition for Henkel, which recognized the rebuilt infrastructure and brand credibility as assets worth paying a premium for.

What Henkel Gets

Henkel is acquiring more than a brand — it is acquiring distribution leverage. OLAPLEX has established direct-to-consumer channels and specialty retail presence across North America that complement Henkel’s broader international footprint. The deal gives Henkel immediate access to the professional stylist and salon community, a channel both companies serve but through different product lines.

For Henkel, the acquisition represents an accelerated path into the premium science-led hair care category without years of organic brand-building. The company gains OLAPLEX’s product innovation pipeline and its recognition among consumers across demographics and hair types.

The Private Equity Exit

Advent International, which controlled a majority of OLAPLEX’s voting stock, approved the transaction by written consent — effectively sealing the deal without requiring a broader shareholder vote. Advent will fully exit its position at closing, bookending an investment that helped build a globally recognized brand even if the public market returns disappointed many retail investors.

J.P. Morgan Securities is advising OLAPLEX on the transaction, which is expected to close in the second half of 2026, pending regulatory approval.

What This Signals for the Market

The OLAPLEX deal underscores a persistent theme in the consumer sector: global strategics are still willing to pay substantial premiums for brands with defensible science-based positioning and professional channel relationships, even when the public market has long since moved on. For small and microcap investors tracking M&A, OLPX is a reminder that a beaten-down stock with genuine brand equity is not always a broken business — sometimes it is just a business waiting for the right buyer.

OLAPLEX will delist from Nasdaq upon closing.

Resolution Minerals Ltd (RLMLF) – Idaho’s Next Gold and Critical Minerals District


Thursday, March 26, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Hans Baldau, Associate Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Initiating coverage with an Outperform. Resolution Minerals Ltd (ASX: RML, OTCQB: RLMLF) is advancing the Horse Heaven Gold–Antimony–Tungsten–Silver Project in Idaho, now covering 14,580 hectares. Following China’s December 2024 ban on antimony exports to the U.S., the country faces a structural supply deficit with no meaningful domestic mining or processing capacity. Resolution is positioned to address this gap through both resource development and intention to build a commercial-scale hydrometallurgical processing facility, aligning the project with U.S. policy priorities around domestic critical mineral supply chains.

Golden Gate. Phase 1 drilling at the Golden Gate Prospect confirmed a fault-controlled Intrusion Related Gold System with indications of meaningful scale. All 14 holes intersected mineralization from surface, including intercepts of 253m at 1.50 g/t Au, 265m at 0.60 g/t Au, and 189m at 1.30 g/t Au, all open at depth, while a second discovery at Golden Gate South expanded the mineralized footprint to more than 1.5km of strike. Importantly, the historical Golden Gate Tungsten Mine, last in production in 1980, is located within Resolution’s property boundary, with management evaluating a restart. A Phase 2 program of up to 45 diamond holes across 13,700 meters commences in early May 2026.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

GeoVax Labs (GOVX) – MVA Vaccine Makes Progress Toward Phase 3 For Mpox


Thursday, March 26, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Mpox Vaccine Clinical Supplies Expected To Be Ready Soon. GeoVax announced the completion of clinical supply testing of GEO-MVA, its modified vaccinia ankara (MVA) vaccine for Mpox/smallpox. The release of vaccine that can be used in clinical trials is expected in early April. This is an important milestone in preparation for the Phase 3 trial planned for late FY2026.

Preparation for Phase 3 Bridging Study and Commercialization. GeoVax is preparing for an immune bridging study to show GEO-MVA stimulates an immune response that is non-inferior to a commercial Mpox vaccine. The study was designed to meet requirements for the European Medicines Agency’s expedited development pathway for Marketing Authorization.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Cardiff Oncology (CRDF) – KOL Discussion Of Onvansertib Supports Our Outperform Rating


Thursday, March 26, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Cardiff Oncology Held A KOL Discussion. On March 25, Cardiff Oncology held a webcast with two world-renown oncologists with experience in drug development and patient treatment. The discussion began with a review of the Phase 2 data by Dr. Mani Mohindru, the Interim CEO. The discussion centered on aspects of the trial, including the outcome data, practical use, and competitive therapies.

The Discussion Included Significance Of Phase 2 Outcomes. The presentation began with a review of Phase 2 data announced in January 2026, with comments by the KOLs. They pointed to the response rate (RR) of 72.2% and the median progression-free survival (PFS) that has not yet been reached. Importantly, onvansertib did not cause additional toxicities to the combination chemotherapy regimen.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

SpaceX Eyes $75 Billion IPO — The Largest in History and What It Means for the Broader Market

SpaceX, Elon Musk’s rocket and satellite giant, is reportedly weighing a fundraising target of approximately $75 billion in its upcoming initial public offering — a figure so staggering it would more than double the previous record holder, Saudi Aramco’s $29 billion listing in 2019. Earlier reports had pegged the target closer to $50 billion, but sources familiar with the matter suggest the company has since discussed raising north of $70 billion with potential investors.

The company is reportedly eyeing a June market debut, with a confidential IPO filing potentially hitting as early as this month. Nothing is finalized, and the timeline could shift, but preparations appear well underway.

At a projected valuation north of $1.75 trillion, SpaceX would sit comfortably among the most valuable companies on the planet — larger than all but five members of the S&P 500. Only Nvidia, Apple, Alphabet, Microsoft, and Amazon would rank above it. That places SpaceX ahead of Meta Platforms and, notably, Musk’s own Tesla. The company’s footprint expanded significantly after absorbing Musk’s AI startup xAI in a deal that valued the combined entity at $1.25 trillion.

For context, SpaceX isn’t just a rocket company anymore. Starlink, its satellite internet division, has become a legitimate global broadband player with millions of subscribers, a recurring revenue engine that makes the broader SpaceX story far more investable than a pure aerospace play. That commercial backbone is a big reason why the valuation math holds up — at least in the eyes of institutional buyers.

Why This Matters Beyond the Headline

For investors who operate in the small and microcap space, this deal carries real implications even if SpaceX is nowhere near your portfolio.

A transaction of this magnitude will consume enormous amounts of institutional capital. Fund managers allocating to a $75 billion raise are, by necessity, pulling liquidity from somewhere. In environments where mega-cap IPOs dominate investor attention, smaller names often get deprioritized — not because the fundamentals have changed, but because the oxygen in the room gets sucked up by the headline deal.

That dynamic has played out historically around blockbuster listings. The Aramco IPO in 2019, the Rivian offering in 2021, and the SPAC boom all coincided with periods of subdued interest in the lower end of the market cap spectrum. Whether SpaceX follows that pattern will depend heavily on the broader macro environment at the time of listing.

There’s also the sentiment angle. A successful SpaceX IPO — executed cleanly at a $1.75 trillion valuation — could serve as a confidence signal for the broader IPO pipeline, potentially unlocking deals that have been sitting on the sidelines waiting for a favorable window. If the market receives this one well, expect a flood of filings in Q3.

For now, the deal is still taking shape. But make no mistake — when a single IPO threatens to rewrite the record books twice over, the entire investment landscape takes note.

Merck Bets $6.7 Billion on a Former Microcap’s CML Drug — TERN Investors Reap the Reward

Merck (NYSE: MRK) announced Tuesday it has entered into a definitive agreement to acquire Terns Pharmaceuticals (Nasdaq: TERN), a clinical-stage oncology company, for $53.00 per share in cash — representing an approximate equity value of $6.7 billion, or roughly $5.7 billion net of acquired cash. The deal carries a 31% premium to Terns’ 60-day volume-weighted average price and a 42% premium to its 90-day VWAP as of March 24, 2026.

The acquisition is a textbook small-cap-to-acquisition story. Less than 18 months ago, Terns was trading below $2 per share with a market cap well under $200 million. By the end of 2025, the stock had surged more than 770% year-to-date on the back of compelling Phase 1 clinical data. As of Tuesday’s announcement, shareholders who held through the volatility are looking at a $53 payday — a return that underscores exactly why early-stage biotech remains one of the most asymmetric bets in the small and microcap universe.

At the center of this deal is TERN-701, an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor (TKI) currently being evaluated in the Phase 1/2 CARDINAL trial for patients with Philadelphia chromosome-positive (Ph+) chronic phase chronic myeloid leukemia (CML). Specifically, the drug targets patients who have already received at least one prior TKI and experienced treatment failure, suboptimal response, or intolerance.

What separates TERN-701 from existing CML therapies is its mechanism and early efficacy signal. The drug is designed to bind to the ABL myristoyl pocket — a distinct binding site from most approved TKIs — giving it the potential to work in patients who have already failed other therapies, including those with difficult resistance mutations like T315I. In clinical data presented through the CARDINAL trial, 64% of efficacy-evaluable patients achieved major molecular response by 24 weeks, with 75% achieving MMR among those treated at doses above 320mg. The safety profile has also been notably clean, with low rates of severe adverse events, minimal blood pressure changes, and low lipase elevation — a meaningful differentiator given the side-effect profiles associated with several competing agents.

The FDA recognized the drug’s potential in March 2024, granting TERN-701 Orphan Drug Designation for the treatment of CML. Merck is now betting that designation translates into a commercially viable, potentially best-in-class therapy within its growing hematology portfolio — which already includes three Phase 3 candidates across leukemias, lymphomas, and myeloproliferative neoplasms.

Merck expects to account for the transaction as an asset acquisition, with the deal expected to close in the second quarter of 2026, pending a successful tender offer and Hart-Scott-Rodino antitrust clearance. The charge will be approximately $5.8 billion, or roughly $2.35 per share, reflected in both Q2 and full-year 2026 results.

For the small and microcap investor community, this deal is more than just a pharma headline. It’s a reminder that the path from sub-$2 clinical-stage company to a multi-billion-dollar buyout target is very much alive — and that the CARDINAL data milestones many overlooked in 2024 were the signals that mattered most.

Ocugen (OCGN) – Raising Price Target After Positive OCU410 Data Reported


Wednesday, March 25, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Top-Line Phase 2 ArMaDa Trial Data Reported. Ocugen reported Phase 2 data for OCU410, its gene therapy for geographic atrophy in dry age-related macular degeneration (GA-dAMD). The data shows clinically meaningful and statistically significant benefit of 31% for treated patients compared with placebo. Based on the trial results, we are including OCU410 revenues in our FY2029 earnings model and raising our price target to $12 per share.

Results Show Preservation of Function and Cell Structure. The primary endpoint showed 31% reduction in lesion growth at the optimal dose (medium) group compared to controls (p< 0.05). A secondary endpoint of photoreceptor cell loss, correlating with visual function, showed a 27% slower rate compared to controls. In addition, 55% of treated patients demonstrated a lesion size reduction of greater than 30% compared with controls.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

First Phosphate Corp. (FRSPF) – NRCan Contribution Agreement Signed; Funding Secured


Wednesday, March 25, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Hans Baldau, Associate Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Investor webinar. CEO John Passalacqua recently presented to investors via Simone Capital. During the call, Mr. Passalacqua commented on the signed contribution agreement with Natural Resources Canada, the ongoing drill program and future feasibility study, the ADR launch, and the strength of the stock in recent weeks relative to a difficult broader market. Management attributed the stock’s resilience to the quality of the shareholder base, consistent milestone execution, and the visible de-risking effect of government backing.

NRCan contribution agreement signed. First Phosphate has executed a formal agreement with Natural Resources Canada providing up to C$16.7 million in non-repayable government funding under the Global Partnerships Initiative. The structure is a reimbursement model, whereby the company incurs eligible expenditures and receives reimbursement of up to 75% within approximately three months, supporting technical and engineering validation work through 2028. Combined with approximately C$20-C$22 million in cash on hand, we estimate total accessible financial resources of approximately C$36-C$38 million, sufficient to fund the company through drill completion, feasibility study, and final investment decision.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.